FOXO4-DRI

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic 46-amino acid peptide designed to selectively eliminate senescent cells -damaged cells that accumulate with age and secrete harmful inflammatory factors (SASP). The peptide uses D-amino acids in reversed sequence, making it resistant to proteolytic degradation while maintaining binding function. FOXO4-DRI works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, causing p53 nuclear exclusion and redirecting it to mitochondria to trigger apoptosis. In mouse studies, it restored fur density, renal function, and physical fitness in aged animals while protecting against chemotherapy-induced toxicity. Notably, it shows 11.73-fold selectivity for senescent over healthy cells. No human clinical trials have been conducted; all efficacy data comes from preclinical animal and cell studies. The peptide was first described by Dr. Peter de Keizer and colleagues at Erasmus University Medical Center in 2017.

• Senescent Cell Clearance
• Tissue Rejuvenation
• Cellular Health

Selective senescent cell elimination, tissue homeostasis restoration, potential anti-aging effects

Disrupts FOXO4-p53 interaction in senescent cells, causing p53 nuclear exclusion. Free p53 translocates to mitochondria, triggering caspase-dependent apoptosis specifically in senescent cells while sparing healthy cells (11.73-fold selectivity demonstrated).

Peak plasma concentration: 4 hrs. Elimination half-life: 1 day – 3 days. Largely cleared by: 5 days – 15 days.

Research protocols from published literature — not dosing recommendations.

• Rapamycin — Avoid Combination: Rapamycin may interfere with senolytic effects by modulating autophagy and cellular stress responses. A 1-2 week washout period is recommended before FOXO4-DRI administration.
• Quercetin — Avoid Combination: Quercetin is itself a senolytic that works through different pathways. Concurrent use may diminish FOXO4-DRI effects. Minimum 96-hour washout, preferably 1-2 weeks.
• Dasatinib — Monitor Combination: Dasatinib + Quercetin is an alternative senolytic cocktail. Different mechanism than FOXO4-DRI. Sequential use may be considered but requires washout periods.
• Corticosteroids — Avoid Combination: Corticosteroids may suppress the apoptotic cascade required for senolytic activity. Avoid concurrent use; washout period recommended.
• Humanin — Compatible: Different mechanisms -Humanin protects healthy cells while FOXO4-DRI clears senescent ones. May be complementary in aging protocols.
• MOTS-C — Unknown: Both target aging pathways but through different mechanisms. MOTS-C focuses on metabolic regulation. No interaction studies available.
• Epitalon — Unknown: Epitalon works through telomerase activation while FOXO4-DRI eliminates senescent cells. Theoretically complementary but no studies on combination.
• 5-Amino-1MQ — Unknown: 5-Amino-1MQ has some senolytic properties through NNMT inhibition. Different mechanism. No data on concurrent use.
• BPC-157 — Unknown: BPC-157 promotes tissue repair while FOXO4-DRI eliminates senescent cells. May be complementary for tissue regeneration but no studies available.
• Chemotherapy Agents — Synergistic: Mouse studies show FOXO4-DRI protects against doxorubicin-induced liver toxicity and may enhance tumor response when clearing senescent cells post-chemotherapy.

Supplies:

• FOXO4-DRI lyophilized powder (typically 10mg vials)
• Bacteriostatic water or sterile water
• Insulin syringes (29-31 gauge)
• Alcohol prep pads

1. 1Store lyophilized powder at -20°C until use
2. 2Allow vial to reach room temperature before reconstitution
3. 3Add sterile water slowly down vial side
4. 4Gently swirl until dissolved -do not shake (protein may denature)
5. 5Solution should be clear; discard if cloudy or precipitated
6. 6Use reconstituted solution within 7-10 days
7. 7Store reconstituted at 2-8°C

Week 1: No reliable human timeline established. Mouse studies: Improvements seen within 1-4 weeks. Fur density restored in aged mice within 2-3 weeks. Renal function normalized within study period (weeks). Human effects poorly characterized; proceed with caution.

CRITICAL: No human clinical trials -all safety data from animal studies. Original mouse studies showed no thrombocytopenia (unlike ABT-737). No cardiac abnormalities on histology in mouse studies. Does not sensitize healthy cells to DNA damage. Anecdotal: Burning/itching at injection site reported. Avoid concurrent use with Rapamycin, Quercetin, corticosteroids. May not be useful for healthy individuals under 40 with low senescent cell burden. Theoretical concern: p53 pathway critical for tumor suppression. Unknown immunogenicity with repeated dosing.

CRITICAL: No human clinical trials -all safety data from animal studies. Original mouse studies showed no thrombocytopenia (unlike ABT-737). No cardiac abnormalities on histology in mouse studies. Does not sensitize healthy cells to DNA damage. Anecdotal: Burning/itching at injection site reported. Avoid concurrent use with Rapamycin, Quercetin, corticosteroids. May not be useful for healthy individuals under 40 with low senescent cell burden. Theoretical concern: p53 pathway critical for tumor suppression. Unknown immunogenicity with repeated dosing.

FOXO4-DRI should be stored at Lyophilized: -20°C. Reconstituted: 2-8°C, use within 7-10 days.